Ablation Device Market

The ablation device market was valued at US$ 9.79 billion in 2024 and is anticipated to reach US$ 17.38 billion by 2031, with an estimated CAGR of 8.5% from 2025 to 2031.

Market Insights and Analyst View:Ablation involves the surgical excision of an organ, structure, or part. Ablation devices utilize heat (typically produced by radio frequency, RF, energy, or lasers) or extreme cold to induce minor burns. The growth of the ablation device market is primarily driven by the rising incidence of chronic diseases, an expanding elderly population, and a growing preference for minimally invasive procedures. However, the strong presence of alternative treatment options and therapies poses a challenge to market expansion.

Growth Drivers and Restraints:The increasing occurrence of chronic diseases, including cancer, cardiovascular diseases, and respiratory ailments, propels the global ablation devices market. Ablation procedures provide effective treatment alternatives for various conditions, such as tumor ablation, cardiac arrhythmias, and pulmonary issues. The World Health Organization (WHO) reports that noncommunicable diseases (NCDs) are responsible for 41 million deaths annually worldwide. Cardiovascular diseases lead NCD deaths, claiming 17.9 million lives each year, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including kidney disease deaths linked to diabetes). Additionally, the National Cancer Institute (NCI) indicates that cancer is increasingly becoming a global health concern. In 2020, over 19.3 million new cancer cases were reported, resulting in approximately 10 million cancer-related deaths globally. The WHO projects that by 2040, there could be 28.9 million new cancer cases and around 16.2 million cancer-related deaths each year. The escalating burden of chronic diseases and the demand for treatment options are driving the need for ablation devices.

Moreover, aging is a significant risk factor for chronic diseases, particularly cardiovascular issues and cancer. The Union for International Cancer Control (UICC) states that aging significantly increases cancer risk, with older adults showing a higher incidence of the disease. The WHO estimates that the percentage of the global population over 60 years will nearly double from 12% to 22% between 2015 and 2050. A study published in January 2023 by NCBI predicts that the number of individuals aged 50 and older in the U.S. will reach 221.13 million by 2050, up from 137.25 million in 2020. It is expected that individuals aged 50 and above will experience at least one chronic disease, with projections indicating a 99.5% increase from 71.52 million in 2020 to 142.66 million by 2050. Additionally, around 14 million people are expected to experience multimorbidity by 2050. Ablation procedures offer minimally invasive treatment options for the elderly, who may face higher surgical risks. Thus, the growing elderly population, combined with the rising prevalence of chronic diseases, drives the expansion of the ablation devices market.

However, ablation techniques encounter competition from alternative treatment options, including surgical procedures, radiation therapy, systemic drug therapies, and other minimally invasive techniques. Healthcare providers may choose alternative treatment modalities based on factors such as effectiveness, safety, patient eligibility, cost-effectiveness, or resource availability, depending on the specific condition being treated. The presence and preference for alternative treatment options can restrict the adoption and use of ablation devices. For instance, traditional cancer treatments like surgery, chemotherapy, and radiation therapy are often favored due to high public awareness, limited adoption of advanced treatments in developing nations, and surgeons' hesitance to move away from conventional methods. Consequently, these factors hinder the growth of the ablation device market.

Strategic Insights

Report Segmentation and Scope:The global ablation device market is categorized by device type, application, and end user. In terms of device type, the market is segmented into radiofrequency devices, laser/light ablation, ultrasound devices, cryoablation devices, and others. By application, the ablation device market is divided into cancer treatment, cardiovascular disease treatment, ophthalmologic treatment, gynecological treatment, urological treatment, cosmetic surgery, and others. Regarding end users, the market is classified into hospitals and clinics, ambulatory surgical centers, and others. Geographically, the ablation device market is segmented into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Russia, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The ablation device market, categorized by device type, includes radiofrequency devices, laser/light ablation, ultrasound devices, cryoablation devices, and others. The radiofrequency devices segment held a significant market share in 2022 and is expected to exhibit a higher CAGR from 2022 to 2030. Radiofrequency ablation is a minimally invasive procedure utilized for treating myomas, bones, tissues, thyroid, endometrium, varicose veins, and more, serving as an alternative to traditional surgical operations.

By application, the ablation device market is segmented into cancer treatment, cardiovascular disease treatment, ophthalmologic treatment, gynecological treatment, urological treatment, cosmetic surgery, and others. The cardiovascular disease treatment segment held a larger market share in 2022 and is also projected to register a higher CAGR during 2022-2030.

In terms of end users, the ablation device market is divided into hospitals and clinics, ambulatory surgical centers, and others. In 2022, the hospitals and clinics segment held the largest market share and is expected to achieve the highest CAGR from 2022 to 2030. Hospitals and clinics are the primary end users of ablation devices, providing a wide range of medical services, including non-invasive procedures that require ablation.

Regional Analysis:Geographically, the global ablation device market is divided into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. Asia Pacific is projected to experience the highest CAGR from 2022 to 2030. Countries in Asia Pacific, such as India and China, present significant growth potential for the ablation devices market. Developing nations in the region, with improving healthcare infrastructure, increasing healthcare spending, and a growing focus on adopting advanced medical technologies, provide opportunities for market growth. As emerging markets invest in healthcare infrastructure and more physicians become familiar with advanced ablation techniques, the demand for ablation devices is expected to rise, enhancing market growth in Asia Pacific.

North America accounted for the largest share of the ablation device market in 2022, with the US holding the largest share of this market. This trend is likely to continue from 2022 to 2030. According to the American Cancer Society, over 1.9 million people were diagnosed with cancer in 2021, resulting in 608,570 deaths. Furthermore, 1 in 2 men and 1 in 3 women in the US are likely to be diagnosed with cancer in their lifetime. This high prevalence of cancer among the population drives the growth of the ablation device market in the US.

The US Centers for Medicare & Medicaid Services reported that national healthcare expenditure in the US rose by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the national Gross Domestic Product (GDP). The US Department of Health & Human Services estimates that national health spending will grow at an annual rate of 5.4% from 2019 to 2028, reaching US$ 6.2 trillion by 2028. An increase in healthcare spending could lead to more funding for research and development related to drugs, thereby boosting the demand for ablation devices in academic settings.

Ablation Device Market Report ScopeIndustry Developments and Future Opportunities:Technological advancements in ablation have greatly enhanced the effectiveness and safety of procedures. Newer ablation devices utilize advanced technologies such as radiofrequency, microwave, cryoablation, and laser, allowing for precise tissue destruction while minimizing damage to surrounding healthy tissues. These innovations have improved success rates and broadened the scope of ablation procedures, driving market growth. Key players in the global ablation device market have undertaken various initiatives, including:

Recent developments in the global ablation device market include:

In May 2023, Abbott received FDA approval for its TactiFlex Ablation Catheter (Sensor Enabled), marking the world's first ablation catheter with a flexible tip and contact force technology.

In February 2023, Hologic Inc.'s NovaSure V5 global endometrial ablation (GEA) device was approved for medical use in Canada and Europe, featuring enhanced capabilities for treating a wide range of cervical and uterine anatomies.

In November 2021, Medtronic India launched the Arctic Front Cardiac Cryoablation Catheter System for atrial fibrillation (AF) treatment, enabling minimally invasive cryoballoon catheter ablation, a therapeutic option for managing AF.

In January 2021, Medtronic plc received FDA approval for the DiamondTemp Ablation (DTA) system, designed for patients with recurrent, symptomatic paroxysmal AF, particularly those unresponsive to conventional drugs. The DTA is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds, currently available for delivering ablations.

In December 2020, Acutus Medical launched the AcQBlate Force Sensing Ablation System in Europe after securing the CE Mark for the AcQBlate Force ablation catheter and the Qubic Force Sensing Module. The AcQBlate Force is the only commercially available gold-tipped, irrigated, force-sensing radiofrequency ablation catheter on the market, integrating advanced components through Acutus Medical's partnership with BIOTRONIK.

In November 2020, Abbott announced the launch of the IonicRF Generator, an FDA-cleared device for delivering a nonsurgical, minimally invasive treatment for managing pain in the nervous system. This RF ablation device targets specific nerves using heat to block pain signals from reaching the brain, and is approved for sale in the US and Europe.

Competitive Landscape and Key Companies:Prominent players in the ablation device market include Abbott Laboratories, AngioDynamics Inc, AtriCure Inc, Biotronik, Boston Scientific Corporation, Conmed Corporation, Johnson and Johnson, Medtronic PLC, Olympus Corporation, and Smith & Nephew PLC. These companies are focused on developing new technologies, enhancing existing products, and expanding geographically to meet the growing global demand and broaden their specialty product portfolios.